within the various disease entities. Treatment outcome was determined by overall survival (OS). IBM SPSS 16 software was used for the statistical analyses. Statistical tests used were the log rank test, the method of Kaplan and Meier, and the chi-square test. P values less than 0.05 were considered significant.
Characteristics of ALK-ALCL are summarized in Table 1 . In contrast to increased age, gender, IPI score, LDH rate, lymphoma's phenotype, and extranodal sites except medullar involvement, advanced Ann Arbor stage and medullar involvement were significant poor prognostic factors (P = 0.004 and P = 0.000, respectively) ( Table 1) .
ALK-ALCL occurs generally in patients with a peak incidence in adults (40-60 years) with preponderance of male [1, 2] . ALK-ALCLs are characterized by unfavorable clinical features (high age and advanced stage at diagnosis, high-risk IPI features) and a poor prognosis which is reported to be better than peripheral T cell lymphoma, not otherwise specified, and to be worse than ALK + ALCL (4, 5, 7). In our study, the OS was 48.5% and this is comparable with prior estimates (30-49%) [2] [3] [4] . Most patients presented with advanced disease (stage III and IV) were all aged more than 50 years, suggesting that ALK-ALCL with advanced stage occurs frequently in adults more than children and young adults. Bone marrow involvement are considered as a prognostic factor either in our study (P = 0.000) or in the literature review [3, 5, 6] . ALK-ALCL was always CD30−, more frequently cytotoxic marker-positive and EMA-positive, and was less likely to express various T cell markers (CD2, CD3, CD4, CD43) [3] .
Other prognostic factors have been reported in the literature including the expression of proteins involved in the regulation of apoptosis and of CD56 [4] and other genetic rearrangements [1] without a real consensus. Advanced Ann Arbor stage and medullar involvement were significant poor prognostic factors (p=0.004 and p=0.000 respectively)
